

1 **SARS-COV-2 IGG DETECTION IN HUMAN ORAL FLUIDS.**

2 Katja Hoschler<sup>1\*</sup>, Samreen Ijaz<sup>1</sup>, Nick Andrews<sup>2</sup>, Sammy Ho<sup>1</sup>, Steve Dicks<sup>3</sup>, Keerthana Jegatheesan<sup>3</sup>,  
3 John Poh<sup>1</sup>, Lenisha Warrener<sup>1</sup>, Thivya Kankeyan<sup>1</sup>, Frances Baawuah<sup>2</sup>, Joanne Beckmann<sup>4</sup>,  
4 Ifeanichukwu O Okike<sup>5</sup>, Shazaad Ahmad<sup>6</sup>, Joanna Garstang<sup>7</sup>, Andrew J Brent<sup>8</sup>, Bernadette Brent<sup>8</sup>,  
5 Felicity Aiano<sup>2</sup>, Kevin E Brown<sup>2</sup>, Mary E Ramsay<sup>2</sup>, David Brown<sup>9</sup>, John V Parry<sup>1</sup>, Shamez N  
6 Ladhani<sup>10</sup>, Maria Zamboni<sup>1</sup>.

7 **\*Correspondence:** Dr Katja Hoschler, Virus Reference Department, Public Health England,  
8 61 Colindale Avenue, London NW9 5EQ, UK. Email: [Katja.Hoschler@phe.gov.uk](mailto:Katja.Hoschler@phe.gov.uk)

9

10 **Word Count:** Abstract 250 words, Main Text (excluding references, legends, tables and figures)  
11 3,017 words

12 **Key words:** Oral fluid, antibody, COVID-19, schools, surveys, children

13 **AFFILIATIONS:**

- 14 1) Virus Reference Department, Public Health England, 61 Colindale Avenue, London NW9  
15 5EQ, UK,  
16 2) Immunisation and Countermeasures Division, Public Health England, 61 Colindale Avenue,  
17 London NW9 5EQ, UK.  
18 3) Virus Reference Department, Public Health England, 61 Colindale Avenue, London NW9  
19 5EQ, UK; Microbiology Services Laboratory, NHS Blood and Transplant  
20 4) East London NHS Foundation Trust, 9 Alie Street, London E1 8DE, UK  
21 5) Derbyshire Healthcare NHS Foundation Trust, 201 London Road, Derby DE1 2TZ, UK  
22 6) Manchester University NHS Foundation Trust, Oxford Road, Manchester M13 9WL, UK  
23 7) Birmingham Community Healthcare NHS Trust, Holt Street, Aston B7 4BN, UK  
24 8) Oxford University Hospitals NHS Foundation Trust, Old Road, Oxford OX3 7HE; University of  
25 Oxford, Wellington Square, Oxford OX1 2JD, UK  
26 9) Virus Reference Department, Public Health England, 61 Colindale Avenue, London NW9  
27 5EQ, UK; Fundação Oswaldo Cruz-Fiocruz, Instituto Oswaldo Cruz, Laboratório de Vírus  
28 Respiratórios e do Sarampo, Rio de Janeiro, RJ, Brasil.  
29 10) Immunisation and Countermeasures Division, Public Health England, 61 Colindale Avenue,  
30 London NW9 5EQ, UK; Paediatric Infectious Diseases Research Group, St. George's  
31 University of London, London SW17 0RE, UK.

32

**NOTE:** This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

### 33 **CONTRIBUTION**

34 KH, SI, SH, TK, KJ and JP developed the assays and performed the laboratory analyses. NA and  
35 JVP performed the data analysis. SNL, FB, JB, IOO, SA, JG, AJB, BB, KEB, and MER devised, set  
36 up and recruited the sKIDs cohort and initiated and completed all the clinical sampling associated with  
37 sample acquisition. SL, JP, DB, SI, MZ and KH led on data interpretation and writing of the  
38 manuscript. All authors reviewed the data, discussed the results and commented on the manuscript.

### 39 **ACKNOWLEDGEMENTS**

40 The authors would like to thank the schools, headteachers, staff, families and their children who took  
41 part in the sKIDs surveillance. The authors would also like to thank the staff in the Virus Reference  
42 Division at PHE Colindale, who supported antibody assay development, sample testing and, staff at  
43 the Immunisation and Countermeasures Division for creation and maintenance of the study database.  
44 Furthermore, we thank members of the Department of Education, Department of Health and Social  
45 Care, London School of Hygiene and Tropical medicine (LSHTM), Office for National Statistics (ONS)  
46 and Scientific Advisory Group for Emergencies (SAGE) for their input and support for the sKIDs  
47 surveillance.

### 48 **FUNDING**

49 This surveillance was funded by the Department of Health and Social Care (DHSC).

50

51 **SARS-COV-2 IGG DETECTION IN HUMAN ORAL FLUIDS.**

52 Katja Hoschler<sup>1\*</sup>, Samreen Ijaz<sup>1</sup>, Nick Andrews<sup>2</sup>, Sammy Ho<sup>1</sup>, Steve Dicks<sup>3</sup>, Keerthana Jegatheesan<sup>3</sup>,  
53 John Poh<sup>1</sup>, Lenisha Warrener<sup>1</sup>, Thivya Kankeyan<sup>1</sup>, Frances Baawuah<sup>2</sup>, Joanne Beckmann<sup>4</sup>,  
54 Ifeanichukwu O Okike<sup>5</sup>, Shazaad Ahmad<sup>6</sup>, Joanna Garstang<sup>7</sup>, Andrew J Brent<sup>8</sup>, Bernadette Brent<sup>8</sup>,  
55 Felicity Aiano<sup>2</sup>, Kevin E Brown<sup>2</sup>, Mary E Ramsay<sup>2</sup>, David Brown<sup>9</sup>, John V Parry<sup>1</sup>, Shamez N  
56 Ladhani<sup>10</sup>, Maria Zamboni<sup>1</sup>.

57 **ABSTRACT**

58 Seroepidemiological studies to monitor antibody kinetics are important for assessing the extent and  
59 spread of SARS-CoV-2 in a population. Non-invasive sampling methods are advantageous to reduce  
60 the need for venepuncture, which may be a barrier to investigations particularly in paediatric  
61 populations. Oral Fluids are obtained by gingiva-crevicular sampling from children and adults and are  
62 very well accepted. ELISA based on these samples have acceptable sensitivity and specificity  
63 compared to conventional serum-based antibody ELISAs and are suitable for population-based  
64 surveillance.

65 We describe the development and evaluation of SARS-COV-2 IgG ELISAs using SARS-CoV-2 viral  
66 nucleoprotein (NP) and spike (S) proteins in IgG isotype capture format and an indirect receptor-  
67 binding-domain (RBD) IgG ELISA, intended for use in children. All three assays were assessed using  
68 a panel of 1999 paired serum and oral fluids from children and adults participating in national primary  
69 school SARS-CoV-2 surveillance studies during and after the first and second pandemic wave in the  
70 UK. The anti NP IgG capture assay was the best candidate, with an overall sensitivity of 75% (95%  
71 CI: 71–79%) specificity of 99% (95% CI: 78–99%) when compared with paired serum antibodies  
72 measured using a commercial assay SARS-CoV-2 nucleoprotein IgG assay (Abbott, Chicago, IL,  
73 USA). Higher sensitivity was observed in children (80%, 95% CI: 71–88%) compared to adults (67%,  
74 CI: 60%-74%). Oral fluid assays using spike protein and RBD antigens were also 99% specific and  
75 achieved reasonable but lower sensitivity in the target population (78%, 95% CI (68%-86%) and 53%,  
76 95% CI (43%-64%), respectively).

77 **Conclusion statement:**

78 Oral Fluid assays based on the detection of SARS-CoV-2 antibodies are a suitable tool for population  
79 based seroepidemiology studies in children.

## 80 INTRODUCTION

81 SARS-CoV-2 virus causes coronavirus disease 2019 (COVID-19), primarily a self-limiting upper  
82 respiratory illness, but can be severe and fatal, especially in older adults (1, 2). Severe COVID-19 is  
83 associated with pneumonia and multi system damage (3) whereas asymptomatic, mild and subclinical  
84 infection is common, particularly in children and adolescents (4). Testing only symptomatic individuals  
85 for acute SARS-CoV-2 infection misses a significant proportion of cases and, therefore,  
86 underestimates the scale and spread of infection, which is critical for understanding transmission. The  
87 presence of SARS-CoV-2 antibodies provides a more robust measure of prior infection, irrespective of  
88 symptom status. Large-scale seroepidemiological programs provide crucial evidence in the monitoring  
89 of the progress of the pandemic and the impact of control measures allowing modelling of the patterns  
90 and trends in antibody responses in the population.

91 The scale of SARS-CoV-2 infection in children and young people is uncertain, and their role in  
92 infection and transmission remains unclear (5, 6). Seroepidemiological programmes based on testing  
93 of residual blood donations and clinical microbiology samples have yielded insights into progress of  
94 the pandemic in England in adults (7, 8), but an important barrier for such programmes, particularly in  
95 younger adults and children, is the availability of large numbers of representative blood samples.

96 The use of oral fluid (OF) for infection surveillance was pioneered in the UK, where it has been  
97 successfully used across a range of pathogens for several decades and to support the evaluation of  
98 the childhood vaccine programme(9-13). Collection is suited to sampling populations such as children  
99 and underserved groups because it does not require the use of venepuncture. The specimen can be  
100 self-collected, guided by videos and pictorial instructions (9).

101 PHE initiated SARS-CoV-2 surveillance in primary schools across England (6). In total, 131 schools  
102 across England were recruited; 86 schools provided weekly nasal swabs for SARS-CoV-2 RT-PCR  
103 and 45 schools provided a blood sample, nasal swab and an oral fluid sample at the beginning and  
104 end of the autumn term in 2020 (6), providing population based materials to assess the feasibility and  
105 performance of oral fluid tests. In this study, we evaluated three different in-house enzyme  
106 immunoassays (EIA) for SARS-CoV-2 antibodies in OF against paired blood samples taken from  
107 children participating in a national surveillance programme.

108

## 109 MATERIALS AND METHODS

### 110 *Ethics Statement*

111 The work described here falls outside of the Health Research Authority remit for ethical review. This is  
112 in accordance with the revised guidance in the Governance Arrangements for Research Ethics  
113 Committees (GAfREC) that was released in September 2011. The surveillance protocol has been  
114 subject to an internal ethical review by the PHE Research Ethics and Governance Group, to ensure  
115 that it is fully compliant with all regulatory requirements and was approved by the Public Health  
116 England Research Ethics Governance Group (R&D REGG Ref: NR0209, 16 May 2020).

117

## 118 ***Recruitment and Sample collection***

119 Headteachers in participating primary schools sent the study information pack to parents and staff at  
120 the start of the study and those interested in taking part were asked to sign a consent form and  
121 complete a short questionnaire. PHE investigators attended the school premises in the period from  
122 28th May – 10th July 2020 and took nasal swabs and blood samples from participating children and  
123 provided guidance and supervision of the oral fluid self-sampling (Table S1, Supplementary  
124 information).

125 The oral fluids were collected on the same day as the paired venous blood, using the Oracol™ foam  
126 swab. This collects gingiva-crevicular fluid when brushing the gum line for 2 minutes, after which the  
127 swab is re-inserted into a plastic container for transportation. Samples are stable for transport at  
128 ambient temperature (14, 15). All samples were couriered to PHE Colindale for same-day processing  
129 and storage.

## 130 ***Oral fluid extraction from Oracol™ swab***

131 On receipt in the laboratory, OF was extracted from the foam swab using 1ml of an elution buffer  
132 (Phosphate buffered saline containing 10% Foetal Calf serum and 250ug/ml Gentamicin and 0.5ug/ml  
133 Fungizone), The swab tube was centrifuged at 3000 g for 5 minutes in bench top centrifuge to remove  
134 cellular debris and, the swab removed and discarded. Samples were stored at -20C prior to testing.

## 135 ***Oral Fluid Assays***

136 Three EIAs were each based on the use of 96-well microplates, and comprised:

- 137 (i) an indirect EIA based on a solid-phase Receptor Binding Domain (RBD) antigen of S  
138 protein and HRP-conjugated anti-human IgG probe (RBD25);
- 139 (ii) IgG isotype antibody capture (GICAP) EIAs based on a solid-phase anti-human IgG with  
140 an HRP-conjugated viral NP probe; or.
- 141 (iii) GICAP EIAs based on a solid-phase anti-human IgG with an HRP-conjugated full-length  
142 viral Spike protein probe

143

144

145 **Laboratory Analysis of oral fluids and sera**

146 ***IgG Capture ELISA NP and S***

147 Solid-phase wells (NUNC Immunomodule, U8 Maxisorp wells) were coated with 100µl volumes of  
148 Affinipure rabbit anti-human  $\gamma$  (Jackson ImmunoResearch, Ely, Cambridgeshire UK) at 5µg/ml in  
149 MicrolImmune Coating Buffer for ELISA with preservative; (ClinTech, Guildford, UK). Coating was  
150 overnight at 2–8°C, followed by 3 hours at 35–37°C. Wells were then washed with PBS Tween 20 and  
151 quenched with MicrolImmune Blocking Solution (ClinTech, Guildford, UK) for 3–4 hours at 37°C. Wells  
152 were aspirated and stored dry at 4°C in sealed pouches with desiccant until use. For both the NP and  
153 S Capture ELISAs, 100µl of oral fluid were added to the wells, incubated for 60 ±2 minutes at 37°C  
154 prior to washing and the addition of the conjugate. One hundred microlitres of HRP conjugated SARS-  
155 CoV-2 full length Spike Glycoprotein (Native Antigen, Oxford, UK) or HRP conjugated SARS-CoV-2  
156 Nucleoprotein (Native Antigen, Oxford, UK) were added to the microwells for the S and NP assays  
157 respectively. After a further incubation for 60 ±2 minutes at 37°C the solid-phase was again washed  
158 and 100µl of substrate added, incubated for 30 ±2 minutes at 37°C, the reaction then stopped and  
159 measured at 450/630nm.

160 ***Indirect anti-RBD IgG ELISA***

161 Oral fluids were analysed with an ELISA established for analysis of sera (16). This indirect ELISA was  
162 modified to allow analysis of oral fluids as follows: 96-well microtiter plates (Nunc, Cat-439454) were  
163 coated with recombinant SARS-CoV-2 RBD (Sino Biological Inc, 25ng/well) incubated with sample at  
164 1:50, and IgG in OF was detected using Biotin conjugated anti-human IgG(Fc) (eBiosciences, Cat:  
165 13-4998-83) followed by detection of the human IgG – anti-human IgG(Fc) complexes using  
166 Streptavidin poly HRP (Thermoscientific, Cat- N200). For analysis, mean optical density (OD) values  
167 were calculated for each study sample, controls and negative OF. Oral fluid samples from SARS-  
168 CoV-2 antibody seronegative individuals and taken prior to the COVID-19 pandemic were used as  
169 negative controls. Results are presented as ratios of the optical density (OD) of the sample to the OD  
170 of the true negative (TN), analysed on the same plate. OD/TN ratios of greater than or equal to 5.0  
171 and 3.0 for serum and OF, respectively, were considered positive.

172 The cut-off value for OF samples for all assays was determined by age group (children and adults)  
173 from the serum-OF pairs, using exploratory sensitivity versus specificity analysis (see supplement  
174 Figure S1 and Table S2) with the result from the commercial serum test considered the true result.  
175 The final cut-off was the value with the highest possible sensitivity retaining the specificity minimum of  
176 98% in both age groups. The final cut-offs were then evaluated by Area Under the Curve (AUC)  
177 Receiver Operating Characteristics (ROC) curve analysis.

178 ***Analysis with commercial EIA***

179 Contemporaneously collected serum samples were tested for SARS-CoV-2 IgG Abbott Architect  
180 SARS-CoV-2 IgG kit; REF 6R86); following the manufacturer's instruction using a cut-off above 0.8 to  
181 determine positivity. SARS-CoV-2 IgG antibody concentrations in oral fluid were measured using the  
182 IgG Human SimpleStep ELISA Kit (Abcam ab195215) according to the manufacturer's instruction.

## 183 **Statistical analysis**

184 Sensitivity and Specificity relative to the Abbott testing on serum was calculated with 95% exact  
185 confidence intervals. This was done at a range of cut-offs by ROC-curve analysis which informed on  
186 the optimal cut-offs. The area under the ROC curve was also calculated with 95% confidence  
187 intervals as an overall measure of assay performance. Assays were compared visually using scatter  
188 plots with logged scaled axes and lines of best fit added and the index of multiple correlation  
189 calculated (R<sup>2</sup>). This was also done to compare results to total IgG. Total IgG was compared between  
190 those positive and negative by Abbott on serum using Tobit regression.

191

## 192 **RESULTS**

193 Paired serum and OF samples from 1,999 subjects were tested (Table S1). SARS-CoV-2 antibody  
194 seropositivity was confirmed in 12% (92/746) of children and 16% (196/1,253) of staff from blood  
195 samples taken during the period of May – July 2020, which is comparable to age-matched antibody  
196 seroprevalence in the local community at the time(6). All OF specimens were assayed for total IgG  
197 concentration. The overall distribution of total IgG in OF collected from students and staff indicated  
198 that 20/1,999 (1.0%) OF specimens had undetectable IgG titres and a further 67/1,999 (3.3%) had an  
199 IgG concentration >0.1 mg/L and <1.0mg/L. Thus, 95.7% (1913/1,999) had an IgG concentration  
200  $\geq 1$ mg/L, with the vast majority (86.8% (1736/1,999))  $\geq 2.0$ mg/L. Total IgG concentrations were not  
201 strongly associated with SARS-CoV-2 antibody positivity (Figure 2).Tobit analysis of logged total IgG  
202 with censoring of IgG concentrations at 1 and 15 and with adjustment for adult/children showed that  
203 the concentration was slightly higher (1.32-fold, 95% CI (1.13-1.55) in those positive compared to  
204 those negative. Children were more likely than adults to provide an OF with no detectable (14/746  
205 [1.9%] versus 6/1,253 [0.5%]) or low (0.2-1 mg/L) IgG antibody titres (57/746 [7.6%] versus 10/1253  
206 [0.8%]).

## 207 **Performance of three OF EIA's**

208 Comparison of serum with oral fluid IgG antibody titres using each of the three OF assays showed a  
209 strong and statistically significant quantitative correlation between the serum IgG signal/cut-off (S/CO)  
210 ratio and each of the oral fluid ELISA antibody titres (Figure 1). The number of discordant results, with  
211 antibody detectable in blood, but not in OF, was most evident with the RBD ELISA, and least evident  
212 with the anti-NP IgG capture ELISA (GICAP). The sensitivities of the GICAP EIAs (NP: 80% & Spike:  
213 78%) were significantly better than the indirect EIA (RBD: 53%) when testing OFs from children, while  
214 specificities were similar, at 99% (Table 1 and Figure S1). ROC curve analysis confirmed the  
215 superiority of the NP and S GICAP EIAs over the indirect RBD ELISA in the correct classification of  
216 oral fluids from children, with the area under the curve (AUC) for both assays statistically larger than  
217 for the RBD ELISA. For OFs from adults (staff), sensitivities were overall lower than for children and  
218 the AUC were comparable, but the NP GICAP EIA was the most sensitive and offered marginally  
219 better specificity than the S GICAP and RBD EIA.

220

## 221 **Utility of Testing Each Oral Fluid Specimen for Total IgG Content**

222 Total IgG concentrations in Oracol™ OF samples increased with age (Figure 3). Overall, there was  
223 poor correlation between total IgG concentrations and SARS-CoV-2 IgG antibody titres for each of the  
224 three OF ELISAs, although there was a declining trend in RBD ELISA IgG titres associated with  
225 declining total IgG concentration for both children and staff (Figure 4). For the GICAP ELISAs, such a  
226 trend was absent for OF samples from children, although there was a modest declining trend in  
227 SARS-CoV-2 IgG antibody titres as total IgG concentrations fell, but much less pronounced than  
228 observed with the RBD ELISA. When OF anti-NP ELISA sensitivity was stratified based on total IgG  
229 concentration, the overall sensitivity remained unchanged until total IgG concentration fell to <1 mg/L  
230 (Figure 4). While OF results in children maintained high sensitivity at all IgG concentrations >1 mg/L,  
231 sensitivity in adults declined as total IgG fell.

232 It was not possible to identify a clear boundary at which total IgG was associated with loss of  
233 sensitivity for SARS-CoV-2 NP IgG detection. An arbitrary total IgG threshold of 0.2 mg/L, or even  
234 1 mg/L, would exclude only 1% or 4.3% of negative specimens, respectively, from prevalence  
235 estimates. This would lead to very small changes in measured prevalence; for example, a  
236 seroprevalence of 20% would change to 20.2% or 20.7%, respectively.

237

## 238 **DISCUSSION**

239 This study forms part of a national programme of SARS-CoV-2 infection and transmission studies in  
240 primary schools whereby paired samples were taken from students and staff to estimate acute  
241 infection and seroprevalence over a six-month period. As part of the study, contemporaneous OF  
242 samples were taken to develop and validate a non-invasive alternative to blood sampling for  
243 seroepidemiological surveillance applications and for use in outbreak investigations.

244 Several viral antigens were evaluated. Viral NP and S proteins are most frequently used in  
245 commercial immunoassays (17). Each virion carries on average more than 2000 copies of the non-  
246 glycosylated NP protein and some data suggests that SARS-CoV-2 NP antibody detection may be  
247 more sensitive than S protein antibody for detecting early infection (18). The NP of SARS-CoV-2  
248 shows between 58% and 65% similarity to NP of seasonal coronaviruses, and cross-reactivity has  
249 been observed in multiple studies (19, 20). The S protein, specifically the RBD region of this protein,  
250 is the target for neutralising antibodies and, antibodies against the S1 subunit of the spike protein or  
251 against RBD have been observed to correlate with neutralising antibody, although not all spike/RBD  
252 antibodies detected in binding assays confer neutralisation (21).

253 For OF sampling, the IgG content of the extracted specimen represents on average a dilution of  
254 approximately 1/1,000 of that in blood plasma. As a result, antibody tests using OFs tend to have  
255 lower sensitivity than those designed for serum, but this analyte is successfully used in  
256 seroepidemiology studies for other viruses e.g. measles and HIV (22-24). The concentration of OFs



257 varies between individual specimens, ranging from <0.5mg/L to >30mg/L (14). This variability in IgG  
258 concentrations makes the choice of assay format more critical. Generally, GICAP antibody tests have  
259 proved to be most robust when detecting viral antibodies in OFs as they are tolerant to the very wide  
260 range of IgG concentration. The strength of any reactivity in a capture assay is dependent on the  
261 proportion of total IgG that is specific for the target antigen, in this case, the SARS-CoV-2 viral  
262 proteins. Consequently, as long as there is sufficient total IgG to saturate the anti-IgG binding sites on  
263 the solid phase, the quantity of captured antibodies, while only a part of the total IgG captured, will be  
264 constant. In our study, measurement of total IgG content to assess OF sample quality revealed a  
265 strong correlation with RBD ELISA reactivity, but not with NP or S protein ELISAs. This reflects the  
266 greater robustness of the IgG isotype capture ELISAs when testing clinical samples, including OFs,  
267 that have highly variable total IgG content. This observation provides some insight into the differences  
268 in anti-SARS-CoV-2 antibody sensitivity between the different OF assays assessed. We also  
269 confirmed lower OF IgG concentrations in young children, which increases with age, reflecting plasma  
270 IgG levels which also increase with age, and this probably explains why the RBD EIA sensitivity was  
271 lower in children than in staff. Other reasons for lower IgG content in children's oral fluids may be  
272 physiological or, in some cases, failure to follow instructions, such as not collecting an OF sample for  
273 the recommended 2 minutes. Overall however the low number of inadequate samples (< 2%) and the  
274 additional costs and demands on laboratory time and facilities associated with measuring total IgG for  
275 every OF sample far outweigh the marginal gain of confirming the quality of the sample for measuring  
276 SARS-CoV-2 antibodies when there is very little impact on assay performance.

277 By comparing three different OF SARS-CoV-2 antibody assays, we found that the sensitivities of the  
278 IgG isotype capture ELISAs (80% for NP, 78% for S) were significantly higher than the indirect ELISA  
279 (RBD, 53%) when testing OFs from children, while specificities were similar at 99% for all three  
280 assays. These results are in keeping with other studies (25-28). Comparison between the two capture  
281 assays is consistent with previous findings that assays based on NP antibodies were more sensitive  
282 than S antibody assays, with the added advantage that anti-NP assays provide earlier detection after  
283 infection compared to S protein antibodies (18, 29). Using multiple antigen formulations in a multiplex  
284 magnetic microparticle assay, the performance with NP based antigens for OFs from adults was  
285 consistently more sensitive than Spike based assays (27). The choice of PCR detection as a  
286 reference comparator to assign infection status, rather than serum measurements of the same  
287 antibody as recently described by Pisanic *et al.*(27) will underestimate the number of infections,  
288 thereby providing an underestimate of serological prevalence and inflating the assumed sensitivity of  
289 the OF assay. A reference classification using a molecular detection assay and a serum antibody  
290 assay in combination and excluding samples from antibody negative, PCR positive individuals, is  
291 expected to improve sensitivity and specificity of an assessed OF assay, as demonstrated in (31).

292 As anticipated, overall sensitivity of detection of SARS CoV-2 IgG OF antibodies was lower than  
293 serum. However, we judge that all three in-house assays were sufficiently accurate for large-scale  
294 use in population-based studies, with statistical adjustment. Taking into consideration the three OF  
295 assays and, the reproducibility, robustness, reagent supply chain and sustainability of service

296 delivery, the IgG isotype specific SARS-CoV-2 NP capture EIA has been adopted as the principal test  
297 for the OF-based SARS-CoV-2 antibody surveillance studies in children. A limitation of using a single  
298 antigen assay, however, is that antibody kinetics may vary over time. Following mild SARS-CoV-2  
299 infection, for example, serum nucleoprotein antibodies decline more rapidly than spike protein  
300 antibodies (19), but this may differ for severe illness and may be also dependent on the assays used  
301 (30). Additionally, little is known about antibody kinetics in children, which may differ over time since  
302 infection. It is, therefore, possible that exclusive use of the NP capture assay may need to be re-  
303 evaluated in future, when antibody from naturally acquired infection starts to wane. Since current  
304 vaccines induce spike protein antibodies, inclusion of a spike protein antibody assay would allow  
305 distinction between antibodies induced following natural infection and/or vaccination, especially in the  
306 context of discussions around vaccination of children. We will continue to evaluate and re-assess the  
307 selected assay with longitudinal oral fluids and serum samples collected from in children and adult  
308 individuals with confirmed SARS-CoV-2 infection.

309

310

## 311 REFERENCES

312

313

- 314 1. Borczuk AC, Salvatore SP, Seshan SV, Patel SS, Bussel JB, Mostyka M, et al. COVID-19  
315 pulmonary pathology: a multi-institutional autopsy cohort from Italy and New York City. *Mod Pathol*.  
316 2020 Nov;33(11):2156-68.
- 317 2. Dennis A, Wamil M, Alberts J, Oben J, Cuthbertson DJ, Wootton D, et al. Multiorgan  
318 impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based  
319 study. *BMJ Open*. 2021 Mar 30;11(3):e048391.
- 320 3. Bryce C, Grimes Z, Pujadas E, Ahuja S, Beasley MB, Albrecht R, et al. Pathophysiology of  
321 SARS-CoV-2: the Mount Sinai COVID-19 autopsy experience. *Mod Pathol*. 2021 Apr 1.
- 322 4. De Luca CD, Esposito E, Cristiani L, Mancino E, Nenna R, Cortis E, et al. Covid-19 in  
323 children: A brief overview after three months experience. *Paediatr Respir Rev*. 2020 Sep;35:9-14.
- 324 5. Ismail SA, Saliba V, Lopez Bernal J, Ramsay ME, Ladhani SN. SARS-CoV-2 infection and  
325 transmission in educational settings: a prospective, cross-sectional analysis of infection clusters and  
326 outbreaks in England. *Lancet Infect Dis*. 2021 Mar;21(3):344-53.
- 327 6. Ladhani SN, Baawuah F, Beckmann J, Okike IO, Ahmad S, Garstang J, et al. SARS-CoV-2  
328 infection and transmission in primary schools in England in June-December, 2020 (sKIDs): an active,  
329 prospective surveillance study. *Lancet Child Adolesc Health*. 2021 Mar 16.
- 330 7. Public Health England. Serological Surveillance of COVID-19 in England: Sera collection  
331 protocol.  
332 [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/89](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/890007/s0036-serological-surveillance-of-covid-19-England-sera-collection-protocol-040320-sage13.pdf)  
333 [0007/s0036-serological-surveillance-of-covid-19-England-sera-collection-protocol-040320-](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/890007/s0036-serological-surveillance-of-covid-19-England-sera-collection-protocol-040320-sage13.pdf)  
334 [sage13.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/890007/s0036-serological-surveillance-of-covid-19-England-sera-collection-protocol-040320-sage13.pdf); 2020.
- 335 8. Public Health England. National COVID-19 surveillance report: 2 October 2020 (week 40).  
336 [https://www.gov.uk/government/publications/national-covid-19-surveillance-reports/sero-surveillance-](https://www.gov.uk/government/publications/national-covid-19-surveillance-reports/sero-surveillance-of-covid-19)  
337 [of-covid-19](https://www.gov.uk/government/publications/national-covid-19-surveillance-reports/sero-surveillance-of-covid-19); 2020.
- 338 9. Parry JV, Perry KR, Mortimer PP. Sensitive assays for viral antibodies in saliva: an alternative  
339 to tests on serum. *Lancet*. 1987 Jul 11;2(8550):72-5.
- 340 10. Perry KR, Brown DW, Parry JV, Panday S, Pipkin C, Richards A. Detection of measles,  
341 mumps, and rubella antibodies in saliva using antibody capture radioimmunoassay. *J Med Virol*. 1993  
342 Jul;40(3):235-40.
- 343 11. Morris-Cunnington MC, Edmunds WJ, Miller E, Brown DW. A population-based  
344 seroprevalence study of hepatitis A virus using oral fluid in England and Wales. *Am J Epidemiol*. 2004  
345 Apr 15;159(8):786-94.

- 346 12. Manikkavasagan G, Bukasa A, Brown KE, Cohen BJ, Ramsay ME. Oral fluid testing during  
347 10 years of rubella elimination, England and Wales. *Emerg Infect Dis.* 2010 Oct;16(10):1532-8.
- 348 13. Maple PA. Application of Oral Fluid Assays in Support of Mumps, Rubella and Varicella  
349 Control Programs. *Vaccines (Basel).* 2015 Dec 9;3(4):988-1003.
- 350 14. Vyse AJ, Cohen BJ, Ramsay ME. A comparison of oral fluid collection devices for use in the  
351 surveillance of virus diseases in children. *Public Health.* 2001 May;115(3):201-7.
- 352 15. Public Health England. COVID-19 Surveillance in Children attending preschool, primary and  
353 secondary schools: COVID-19 Surveillance in school KIDs (code: sKIDs).  
354 [https://www.gov.uk/government/publications/covid-19-surveillance-in-school-kids-skids-pre-and-](https://www.gov.uk/government/publications/covid-19-surveillance-in-school-kids-skids-pre-and-primary-schools)  
355 [primary-schools](https://www.gov.uk/government/publications/covid-19-surveillance-in-school-kids-skids-pre-and-primary-schools); 2020.
- 356 16. Harris RJ, Whitaker HJ, Andrews NJ, Aiano F, Amin-Chowdhury Z, Flood J, et al. Serological  
357 surveillance of SARS-CoV-2: Six-month trends and antibody response in a cohort of public health  
358 workers. *J Infect.* 2021 Mar 22.
- 359 17. Li D, Li J. Immunologic testing for SARS-CoV-2 infection from the antigen perspective. *J Clin*  
360 *Microbiol.* 2020 Dec 14.
- 361 18. Burbelo PD, Riedo FX, Morishima C, Rawlings S, Smith D, Das S, et al. Detection of  
362 Nucleocapsid Antibody to SARS-CoV-2 is More Sensitive than Antibody to Spike Protein in COVID-19  
363 Patients. *medRxiv.* 2020 Apr 24.
- 364 19. McAndrews KM, Dowlathshahi DP, Dai J, Becker LM, Hensel J, Snowden LM, et al.  
365 Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with  
366 implications for COVID-19 immunity. *JCI Insight.* 2020 Sep 17;5(18).
- 367 20. Anderson EM, Goodwin EC, Verma A, Arevalo CP, Bolton MJ, Weirick ME, et al. Seasonal  
368 human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with  
369 protection. *Cell.* 2021 Apr 1;184(7):1858-64 e10.
- 370 21. Amanat F, Thapa M, Lei T, Ahmed SMS, Adelsberg DC, Carreno JM, et al. The plasmablast  
371 response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing antibodies that target  
372 both the NTD and the RBD. *medRxiv.* 2021 Mar 9.
- 373 22. Pascoe SJ, Langhaug LF, Mudzori J, Burke E, Hayes R, Cowan FM. Field evaluation of  
374 diagnostic accuracy of an oral fluid rapid test for HIV, tested at point-of-service sites in rural  
375 Zimbabwe. *AIDS Patient Care STDS.* 2009 Jul;23(7):571-6.
- 376 23. Roberts KJ, Grusky O, Swanson AN. Outcomes of blood and oral fluid rapid HIV testing: a  
377 literature review, 2000-2006. *AIDS Patient Care STDS.* 2007 Sep;21(9):621-37.
- 378 24. Vyse AJ, Gay NJ, White JM, Ramsay ME, Brown DW, Cohen BJ, et al. Evolution of  
379 surveillance of measles, mumps, and rubella in England and Wales: providing the platform for  
380 evidence-based vaccination policy. *Epidemiol Rev.* 2002;24(2):125-36.
- 381 25. Ben Salah A, Zaatour A, Pomery L, Cohen BJ, Brown DW, Andrews N. Validation of a  
382 modified commercial assay for the detection of rubella-specific IgG in oral fluid for use in population  
383 studies. *J Virol Methods.* 2003 Dec;114(2):151-8.
- 384 26. Saleh LH. The use of saliva for the detection of IgG and anti-bodies against rubella virus:  
385 comparison of indirect ELISA and antibody capture immunoassay. *J Egypt Public Health Assoc.*  
386 1991;66(1-2):123-34.
- 387 27. Pisanic N, Randad PR, Kruczynski K, Manabe YC, Thomas DL, Pekosz A, et al. COVID-19  
388 Serology at Population Scale: SARS-CoV-2-Specific Antibody Responses in Saliva. *J Clin Microbiol.*  
389 2020 Dec 17;59(1).
- 390 28. Isho B, Abe KT, Zuo M, Jamal AJ, Rathod B, Wang JH, et al. Persistence of serum and saliva  
391 antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients. *Sci Immunol.* 2020 Oct  
392 8;5(52).
- 393 29. Popovic M, Minceva M. Thermodynamic insight into viral infections 2: empirical formulas,  
394 molecular compositions and thermodynamic properties of SARS, MERS and SARS-CoV-2 (COVID-  
395 19) viruses. *Heliyon.* 2020 Sep;6(9):e04943.
- 396 30. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in  
397 patients discharged from hospital: a cohort study. *Lancet.* 2021 Jan 16;397(10270):220-32.

398

399

400 **FIGURE LEGENDS**

401 Figure 1: Scattergrams of Abbot Architect IgG anti-SARS-CoV-2 S/CO determined in sera versus test  
402 result determined from concomitantly collected and paired oral fluids analysed in: 1a) IgG Anti SARS-  
403 CoV-2 (RBD, indirect format) 1b) IgG Anti SARS-CoV-2 (Spike, capture format) and 1c) IgG Anti  
404 SARS-CoV-2 (NP, capture format). – All data log transformed. Data from children is shown in solid  
405 black dots and samples from staff (adults) are shown in grey circles; numbers are shown in graph.  
406 Dotted lines represent data trends in each assay.

407 Figure 2: Distribution of total IgG in OF by serum result (from Abbot Architect analyser)

408 Figure 3: Scattergram of Total IgG measured in Oral Fluid by age of subject (children only; 708  
409 children with known age included. Dotted line indicates trend)

410 Figure 4: Scattergrams of total IgG concentration (in mg/L) determined in oral fluids versus test result  
411 determined in: 1a) IgG Anti SARS-CoV-2 (RBD, indirect format) 1b) IgG Anti SARS-CoV-2 (Spike,  
412 capture format) and 1c) IgG Anti SARS-CoV-2 (NP, capture format). Data from children is shown in  
413 solid black dots and samples from staff (adults) are shown in grey circles. – All data log transformed.  
414 The detection limit for the total IgG determination is 15mg/ml – data points from samples with IgG  
415 >15mg/L were excluded from graphs. Number of samples from children: n=619, number of samples  
416 from adults/staff: N=695. Dotted lines represent data trends in each assay, R2 values are given for  
417 each trend.

418

419  
420  
421  
422  
423

**Table 1:** Sensitivity and specificity findings for the 3 Oral Fluid IgG anti-SARS-CoV-2 ELISAs at their optimal cut-off based on status based on a serum test in the Abbott Architect SARS-CoV-2 IgG Assay.

	Cut-off	Sensitivity (95% CI)	n/N	Specificity (95% CI)	n/N
<b>Children (n=746)</b>					
RBD indirect	3.0	53% (43%-64%)	49/92	99% (98% - 100%)	649/654
Spike capture	1.0	78% (68%-86%)	71/91 <sup>a</sup>	99% (98% - 100%)	645/650 <sup>b</sup>
Nucleoprotein capture	1.0	80% (71%-80%)	73/91 <sup>a</sup>	99% (98% - 100%)	644/650 <sup>b</sup>
<b>Staff (n=1,253)</b>					
RBD indirect	3.0	60% (53%-67%)	117/196	98% (97% - 99%)	1035/1057
Spike capture	1.0	58% (51%-65%)	113/195 <sup>c</sup>	99% (98% - 99%)	1044/1056 <sup>d</sup>
Nucleoprotein capture	1.0	67% (60%-74%)	131/195 <sup>c</sup>	99% (98% - 99%)	1041/1056 <sup>d</sup>

424  
425  
426  
427  
428  
429  
430  
431


<sup>a, b, d</sup> A single specimen from each of these categories was of insufficient volume to permit testing by the 2 IgG capture assays.  
<sup>c</sup> Four specimens from this category were of insufficient volume to permit testing by the 2 IgG capture assays.

**Table 2:** Sensitivity of GISAC EIA for detection of IgG anti-SARS-CoV-2 NP antibody in oral fluid specimens by total IgG concentration.

IgG Conc.	Seropositive Children			Seropositive Staff			Seropositive Overall		
	NP Positive	NP Negative	% Positive	NP Positive	NP Negative	% Positive	NP Positive	NP Negative	% Positive
>10mg/L	22	7	75.9%	94	39	70.7%	116	46	71.6%
2-10mg/L	37	7	84.1%	34	20	63.0%	71	27	72.4%
1-2mg/L	12	2	85.7%	3	3	50.0%	15	5	75.0%
<1mg/L	2	2	50.0%	0	2	0.0%	2	4	33.3%
<b>Overall</b>	<b>73</b>	<b>18</b>	<b>80.2%</b>	<b>131</b>	<b>64</b>	<b>67.2%</b>	<b>204</b>	<b>82</b>	<b>71.3%</b>

432  
433

434 **Figure 1:** Scattergrams of Abbot Architect IgG anti-SARS-CoV-2 S/CO determined in sera versus test  
435 result determined from concomitantly collected and paired oral fluids  
436



437

438 **Figure 2:** Distribution of total IgG in OF by serum result (from Abbot Architect analyser)

439


440

441

442

443


444




445 **Figure 3:** Scattergram of Total IgG measured in Oral Fluid by age of subject (children only; 708

446 children with known age included. Dotted line indicates trend)

447



448 **Figure 4:** Scattergrams of total IgG concentration (in mg/L) determined in oral fluids versus test result  
449  
450





451 **Supplement**

452


453 **Table S1:** Summary of participant characteristics

	Staff (Adults)	Children	Total
<b>Number of participants</b>	<b>1253</b>	<b>746</b>	<b>1999</b>
<b>Period of collection</b>	<b>28<sup>th</sup> May – 10<sup>th</sup> July</b>		
<b>Male (%)</b>	<b>242 (19.31%)</b>	<b>377 (50.54%)</b>	<b>619 (30.97%)</b>
Sex unknown	30 (2.39%)	21 (2.82%)	51 (2.55%)
<b>Age at sampling median (min - max)</b>	<b>43 (22–71yrs)</b>	<b>8 (0–19yrs)</b>	<b>11 (0–71yrs)</b>
Age unknown	750 (59.86%)	37 (4.96%)	787 (39.37%)
Oral fluids with paired serum analysed in Abbot	1253 (100.00%)	746 (100.00%)	1999 (100.00%)
Paired OF with result in N capture	1251 (99.84%)	741 (99.33%)	1992 (99.65%)
Paired OF with result in S capture	1251 (99.84%)	741 (99.33%)	1992 (99.65%)
Paired OF with result in RBD indirect	1253 (100.00%)	746 (100.00%)	1999 (100.00%)
<b>OF with results for all three OF ELISA's and data on total IgG</b>	<b>1251 (99.84%)</b>	<b>741 (99.33%)</b>	<b>1992 (99.65%)</b>

454

455

456 **Figure S1:** ROC Analysis



457 **Area Under the Curve results (95% confidence Intervals)**

Assay	RBD	Spike	NP
sKIDS child	0.897 (0.873-0.918)	0.942 (0.923-0.958)	0.939 (0.92-0.955)
sKIDS adult	0.874 (0.854-0.892)	0.874 (0.855-0.892)	0.879 (0.86-0.897)

458 ROC (vs Abbot>=0.8)

459

460

461

462

463

464

465

466

467

468

469

470  
471  
472  
473  
474  
475

**Table S2: Sensitivity and Specificity at a range of cut-offs based on serostatus determined by Abbot Architect (cut-off at 0.8)**

	RBD					NP					Spike					
	cut	n/N	Sens	n/N	Spec	cut	n/N	Sens	n/N	Spec	cut	n/N	Sens	n/N	Spec	
sKIDS child	2	66/92	0.72 (0.61-0.81)	633/654	0.97 (0.95-0.98)	0.7	79/91	0.87 (0.78-0.93)	582/650	0.90 (0.87-0.92)	0.7	79/91	0.87 (0.78-0.93)	540/650	0.83 (0.80-0.86)	
	2.2	62/92	0.67 (0.57-0.77)	638/654	0.98 (0.96-0.99)	0.8	77/91	0.85 (0.76-0.91)	617/650	0.95 (0.93-0.97)	0.8	73/91	0.80 (0.71-0.88)	609/650	0.94 (0.92-0.95)	
	2.4	58/92	0.63 (0.52-0.73)	643/654	0.98 (0.97-0.99)	0.9	76/91	0.84 (0.74-0.91)	631/650	0.97 (0.96-0.98)	0.9	72/91	0.79 (0.69-0.87)	636/650	0.98 (0.96-0.99)	
	2.6	53/92	0.58 (0.47-0.68)	647/654	0.99 (0.98-1)	1	73/91	0.80 (0.71-0.88)	644/650	0.99 (0.98-1)	1	71/91	0.78 (0.68-0.86)	645/650	0.99 (0.98-1)	
	2.8	51/92	0.55 (0.45-0.66)	648/654	0.99 (0.98-1)	1.1	71/91	0.78 (0.68-0.86)	645/650	0.99 (0.98-1)	1.1	66/91	0.73 (0.62-0.81)	648/650	1 (0.99-1)	
	3	49/92	0.53 (0.43-0.64)	649/654	0.99 (0.98-1)	1.2	69/91	0.76 (0.66-0.84)	645/650	0.99 (0.98-1)	1.2	59/91	0.65 (0.54-0.75)	649/650	1 (0.99-1)	
	3.2	47/92	0.51 (0.40-0.62)	650/654	0.99 (0.98-1)	1.3	65/91	0.71 (0.61-0.80)	646/650	0.99 (0.98-1)	1.3	52/91	0.57 (0.46-0.68)	650/650	1 (0.99-1)	
sKIDS adult	2	137/196	0.70 (0.63-0.76)	977/1057	0.92 (0.91-0.94)	0.7	148/195	0.76 (0.69-0.82)	941/1056	0.89 (0.87-0.91)	0.7	151/195	0.77 (0.71-0.83)	896/1056	0.85 (0.83-0.87)	
	2.2	134/196	0.68 (0.61-0.75)	995/1057	0.94 (0.93-0.96)	0.8	141/195	0.72 (0.66-0.79)	986/1056	0.93 (0.92-0.95)	0.8	137/195	0.70 (0.63-0.77)	978/1056	0.93 (0.91-0.94)	
	2.4	127/196	0.65 (0.58-0.72)	1006/1057	0.95 (0.94-0.96)	0.9	140/195	0.72 (0.65-0.78)	1016/1056	0.96 (0.95-0.97)	0.9	128/195	0.66 (0.59-0.72)	1022/1056	0.97 (0.96-0.98)	
	2.6	124/196	0.63 (0.56-0.70)	1019/1057	0.96 (0.95-0.97)	1	131/195	0.67 (0.60-0.74)	1041/1056	0.99 (0.98-0.99)	1	113/195	0.58 (0.51-0.65)	1044/1056	0.99 (0.98-0.99)	
	2.8	122/196	0.62 (0.55-0.69)	1026/1057	0.97 (0.96-0.98)	1.1	125/195	0.64 (0.57-0.71)	1043/1056	0.99 (0.98-0.99)	1.1	99/195	0.51 (0.44-0.58)	1046/1056	0.99 (0.98-1)	
	3	117/196	0.60 (0.53-0.67)	1035/1057	0.98 (0.97-0.99)	1.2	121/195	0.62 (0.55-0.69)	1044/1056	0.99 (0.98-0.99)	1.2	86/195	0.44 (0.37-0.51)	1047/1056	0.99 (0.98-1)	
		3.2	109/196	0.56 (0.49-0.63)	1039/1057	0.98 (0.97-0.99)	1.3	119/195	0.61 (0.54-0.68)	1045/1056	0.99 (0.98-1)	1.3	78/195	0.40 (0.33-0.47)	1047/1056	0.99 (0.98-1)

476